Literature DB >> 28433402

Sensing Bad: Are Co-stimulatory CAR-Expressing γδ T Cells Safer?

Robin Parihar1.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28433402      PMCID： PMC5417836          DOI： 10.1016/j.ymthe.2017.04.012

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  13 in total

1.  Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.

Authors:  Richard A Morgan; James C Yang; Mio Kitano; Mark E Dudley; Carolyn M Laurencot; Steven A Rosenberg
Journal:  Mol Ther       Date:  2010-02-23       Impact factor: 11.454

2.  Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo.

Authors:  Evripidis Lanitis; Mathilde Poussin; Alex W Klattenhoff; Degang Song; Raphael Sandaltzopoulos; Carl H June; Daniel J Powell
Journal:  Cancer Immunol Res       Date:  2013-07       Impact factor: 11.151

3.  Avoidance of On-Target Off-Tumor Activation Using a Co-stimulation-Only Chimeric Antigen Receptor.

Authors:  Jonathan Fisher; Pierre Abramowski; Nisansala Dilrukshi Wisidagamage Don; Barry Flutter; Anna Capsomidis; Gordon Weng-Kit Cheung; Kenth Gustafsson; John Anderson
Journal:  Mol Ther       Date:  2017-03-22       Impact factor: 11.454

4.  Chimeric antigen receptor T cells for sustained remissions in leukemia.

Authors:  Shannon L Maude; Noelle Frey; Pamela A Shaw; Richard Aplenc; David M Barrett; Nancy J Bunin; Anne Chew; Vanessa E Gonzalez; Zhaohui Zheng; Simon F Lacey; Yolanda D Mahnke; Jan J Melenhorst; Susan R Rheingold; Angela Shen; David T Teachey; Bruce L Levine; Carl H June; David L Porter; Stephan A Grupp
Journal:  N Engl J Med       Date:  2014-10-16       Impact factor: 91.245

Review 5.  Engineered T cells: the promise and challenges of cancer immunotherapy.

Authors:  Andrew D Fesnak; Carl H June; Bruce L Levine
Journal:  Nat Rev Cancer       Date:  2016-08-23       Impact factor: 60.716

Review 6.  Nonpeptide antigens, presentation mechanisms, and immunological memory of human Vgamma2Vdelta2 T cells: discriminating friend from foe through the recognition of prenyl pyrophosphate antigens.

Authors:  Craig T Morita; Chenggang Jin; Ghanashyam Sarikonda; Hong Wang
Journal:  Immunol Rev       Date:  2007-02       Impact factor: 12.988

Review 7.  gammadelta T cells in cancer immunotherapy: current status and future prospects.

Authors:  Shubhada Chiplunkar; Swati Dhar; Daniela Wesch; Dieter Kabelitz
Journal:  Immunotherapy       Date:  2009-07       Impact factor: 4.196

8.  Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.

Authors:  Marco L Davila; Isabelle Riviere; Xiuyan Wang; Shirley Bartido; Jae Park; Kevin Curran; Stephen S Chung; Jolanta Stefanski; Oriana Borquez-Ojeda; Malgorzata Olszewska; Jinrong Qu; Teresa Wasielewska; Qing He; Mitsu Fink; Himaly Shinglot; Maher Youssif; Mark Satter; Yongzeng Wang; James Hosey; Hilda Quintanilla; Elizabeth Halton; Yvette Bernal; Diana C G Bouhassira; Maria E Arcila; Mithat Gonen; Gail J Roboz; Peter Maslak; Dan Douer; Mark G Frattini; Sergio Giralt; Michel Sadelain; Renier Brentjens
Journal:  Sci Transl Med       Date:  2014-02-19       Impact factor: 17.956

Review 9.  Clinical applications of gamma delta T cells with multivalent immunity.

Authors:  Drew C Deniger; Judy S Moyes; Laurence J N Cooper
Journal:  Front Immunol       Date:  2014-12-11       Impact factor: 7.561

10.  Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells.

Authors:  Christopher C Kloss; Maud Condomines; Marc Cartellieri; Michael Bachmann; Michel Sadelain
Journal:  Nat Biotechnol       Date:  2012-12-16       Impact factor: 54.908
View more
  1 in total

Review 1.  Recent advances in CAR-T cell engineering.

Authors:  Ruihao Huang; Xiaoping Li; Yundi He; Wen Zhu; Lei Gao; Yao Liu; Li Gao; Qin Wen; Jiang F Zhong; Cheng Zhang; Xi Zhang
Journal:  J Hematol Oncol       Date:  2020-07-02       Impact factor: 17.388
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.